DSM Nutritional Products Ltd

Kaiseraugst, Switzerland

DSM Nutritional Products Ltd

Kaiseraugst, Switzerland

Time filter

Source Type

News Article | May 15, 2017
Site: marketersmedia.com

— Various health benefits of herbal supplements, increasing use of functional foods and consumer awareness for preventive healthcare measures will drive the market growth. However, stringent regulations and high raw material cost will hamper market growth. Demand for dietary supplements among women and acquisition of small nutraceutical companies by pharmaceutical manufacturers will provide ample opportunity to grow. Few major trends would be increased demand for multi component botanical formulations, and major companies are performing extensive research to produce phytomedicines and herbal supplements in dentistry. Pharmaceutical industry is the fastest growing segment in Herbal Supplements application market due to the consumer’s reliability in the quality and effectiveness of herbal supplements. Retail store segment dominated the distribution channel market segment owing to rise in disposable income and favorable investment for infrastructure. Multi Herbs in product segment is the fastest growing market because of the need for multifunctional medications. Soy and specialty herbs are expected to grow lucratively. North America and Europe accounted for the largest market share with significant growth because of consumer awareness and product availability. In countries such as France, Germany and UK herbal supplements are sold in drugstores. Asia Pacific is witnessed to be the fastest growing market owing to huge consumer base particularly women. Some of the key players in global Herbal Supplements market are Archer Daniels Midland Company, Arizona Natural Products, Bio-Botanica Inc., Blackmores Ltd, Gaia Herbs, Glanbia PLC, Herb Pharm, Herbalife International of America, Inc., Naturalife Asia Co., Ltd., Nature’s Bounty, Dr. Willmar Schwabe GmbH & Co. KG, Nutraceutical International Corporation, Rainbow Light Nutritional Systems, Ricola AG, The Himalaya Drug Company, Twinlab Corporation and DSM Nutritional Products Ltd. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 8 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


Hahn C.,University of Oslo | Bachmann L.,University of Oslo | Chevreux B.,DSM Nutritional Products Ltd.
Nucleic Acids Research | Year: 2013

We present an in silico approach for the reconstruction of complete mitochondrial genomes of non-model organisms directly from next-generation sequencing (NGS) data - mitochondrial baiting and iterative mapping (MITObim). The method is straightforward even if only (i) distantly related mitochondrial genomes or (ii) mitochondrial barcode sequences are available as starting-reference sequences or seeds, respectively. We demonstrate the efficiency of the approach in case studies using real NGS data sets of the two monogenean ectoparasites species Gyrodactylus thymalli and Gyrodactylus derjavinoides including their respective teleost hosts European grayling (Thymallus thymallus) and Rainbow trout (Oncorhynchus mykiss). MITObim appeared superior to existing tools in terms of accuracy, runtime and memory requirements and fully automatically recovered mitochondrial genomes exceeding 99.5% accuracy from total genomic DNA derived NGS data sets in <24 h using a standard desktop computer. The approach overcomes the limitations of traditional strategies for obtaining mitochondrial genomes for species with little or no mitochondrial sequence information at hand and represents a fast and highly efficient in silico alternative to laborious conventional strategies relying on initial long-range PCR. We furthermore demonstrate the applicability of MITObim for metagenomic/pooled data sets using simulated data. MITObim is an easy to use tool even for biologists with modest bioinformatics experience. The software is made available as open source pipeline under the MIT license at https://github.com/chrishah/MITObim. © 2013 The Author(s) 2013. Published by Oxford University Press.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2013.2.2-03 | Award Amount: 7.95M | Year: 2013

Vitamin D deficiency has significant implications for human health and impacts on healthy growth and development and successful aging. Fundamental knowledge gaps are barriers to implementing a safe and effective public health strategy to prevent vitamin D deficiency and optimize status. ODIN will provide the evidence to prevent vitamin D deficiency in Europe and improve nutrition and public health through food. By establishing an internationally standardized analytical platform for 25OHD, ODIN will measure the distribution of circulating 25OHD and describe the prevalence of vitamin D deficiency in Europe. Using available biobanks and databases from National nutrition surveys ODIN will delineate the relative contributions of sun and dietary sources of vitamin D to circulating 25OHD. In support of planned EFSA revisions of vitamin D recommendations, ODIN will carry out three RCT in pregnant women, children and teenagers and a fourth RCT in ethnic immigrant groups to provide experimental data to specify vitamin D intake requirements. Using dietary modeling, innovative food-based solutions to increase vitamin D in the food supply through a combination of bio-fortification of meats, fish, eggs, mushrooms and yeast will be developed and ODIN will test the efficacy and safety of these products in food-based RCT varying in scale from small product-specific trials to a large total diet study in vulnerable indigenous and immigrant sub-groups. ODIN has assembled the largest critical mass of prospective adult, pregnancy and birth cohort studies to date and will conduct meta-analyses and individual subject-level meta-regression analyses to integrate standardized data on vitamin D status, a priori defined clinical endpoints and genotype to examine relationships between vitamin D and human health, including beneficial and adverse effects, on perinatal outcomes, bone growth and body composition and allergic disease in children and cardiovascular disease and mortality in adults.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2010.2.3-02 | Award Amount: 12.29M | Year: 2011

The present proposal sees the development of business and value creation models as central to the development of personalised nutrition and thus it is intended to engage in a series of interviews with key stakeholders, which will generate a number of scenarios to be considered by these stakeholders. Parallel to that we will run some focus groups with consumers and develop a tool to ascertain consumer attitudes to personalised nutrition in 8 EU countries (1,000 per country) representing a breadth of gastronomic traditions. Within these 8 countries, we will recruit 1,280 subjects and offer 3 levels of personalised nutrition: 1 Personalised dietary advice alone; 2: personalised dietary advice based on biochemical phenotypic data; 3: the latter to include genomic data. These will be compared with a control group, which will be offered non-personalised dietary advice. All of the data on dietary intake and all of the advice will be Internet delivered and will last 6 months. Within each of the 3 levels of personalised nutrition groups, half will receive their feedback at months 0, 3 and 6 while the other half will have continuous feedback on demand with intensive coaching. The overall outcome measurement will be changes in a healthy eating index. The data gathered in this study will feed into the development of algorithms to provide automated feedback for future services delivering personalised advice on food choice. We will bring together an international group of experts to develop best practice in the application of all aspects of nutrigenomic research to personalised nutrition. We will also scope out existing and future technologies, particularly those involving biofeedback, which will help the development of personalised nutrition. Finally we develop position papers on the ethical and legal aspects of personalised nutrition. Permeating all of this work will be a wide-ranging communications programme aimed at all stakeholders of relevance to personalised nutrition.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: NMP.2012.3.0-1 | Award Amount: 5.48M | Year: 2012

The proposed project, MAPSYN, aims to bring selected innovative energy efficient chemical reaction processes, assisted with novel microwave, ultrasonic and plasma systems, up to the manufacturing scale. A pragmatic approach of using these selected alternative energy sources for end user selected reactions, will be individually studied for both microreactor and flow reactor systems (i.e. continuous not batch processes), to address specific business drivers such as energy reduction or increased production. The cost and energy of production needs to be kept as lean as possible with quality, reproducibility and sustainability being at the centre of the novel MAPSYN process concepts. Fine and commodity chemical syntheses for the chemical industry can be energy, time and design skill intensive and may produce lower reaction yields than desired. These valuable chemicals are vital to the consumer as they are used by the personal care, pharmaceutical, household and agricultural industries. End user selected reactions include selective hydrogenations and nitrogen fixation reactions.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.2.2-1 | Award Amount: 13.07M | Year: 2012

As the European population is ageing rapidly, the growing number of seniors with age-related chronic diseases poses a challenge on European societies and health care systems. Therapeutic interventions that are effective, affordable and well-tolerated in the prevention of chronic disease are urgently needed and will have an outstanding impact on public health as a whole. Among the most promising interventions that meet these requirements are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a clinical trial. The DO-HEALTH will close this knowledge gap in a large 3-year multi-centre clinical trial that will establish long-term efficacy and safety data for the 3 interventions in the prevention of age-related diseases in seniors. The DO-HEALTH trial will enrol 2152 community-dwelling men and women aged 70 and older, when chronic diseases increase substantially. The randomized-controlled trial will test the individual and the combined benefit of 2000 IU vitamin D/day, 1 g of omega-3 fatty acids/day and a simple home exercise program in an efficient factorial trial design. DO-HEALTH will establish evidence in 5 primary endpoints: the risk of incident non-vertebral fractures; the risk of functional decline; the risk of blood pressure increase; the risk of cognitive decline; and the rate of any infection. Key secondary endpoints include risk of hip fracture, rate of falls, pain in symptomatic knee osteoarthritis, glucose tolerance, gastro-intestinal symptoms, mental and oral health, quality of life, and mortality. Follow-up will be in-person, in 3-monthly intervals (4 clinical visits and 9 phone calls). DO-HEALTH will further assess the comparative effectiveness of the interventions by evaluating reasons why or why not seniors adhere to them, and will assess their cost-benefit in a health economic model based on documented health care utilization and observed incidence of chronic disease.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: CBTT-1-2014 | Award Amount: 2.33M | Year: 2015

Innovation is at the heart of Europes growth strategy. However, Europe lags behind its international competitors in converting investment in Public Research Organisation PRO research into commercial returns via innovation. The solution lies in improving the transfer of technology from PROs to industry but there are many barriers to effective technology transfer, including: Most Technology Transfer Offices (TTOs) in PROs are small, underfunded and under-skilled; a small investor pool and long timescales make it difficult to secure finance and; there is poor understanding between IP creators, exploiters, funders and end-users. To address these barriers, PROGRESS-TT will transfer the expertise of Europes leading PROs to those with the greatest potential to grow. We will gather best practice from leading PROs and thought leaders and formulate it into Europes most definitive TT tools, methods and insight. We will then begin a programme of knowledge transfer tailored to the audiences level of readiness to grow. This will include: Training, workshops, boot camps and e-learning delivered to emerging PROs and TT funds to develop their core skills Intensive coaching and mentoring for high potential PROs to accelerate their TT activity. We will form teams comprising experienced TTO performers, industry, funds and high potential PROs to develop capability, capacity, opportunity, desire, and to build a supportive TT environment. Improving access to finance by bringing established and emerging funds together to share best practice and identify cross-border opportunities We will continuously improve best practice based on our trial activities, in order to create a validated legacy programme to continue supporting PROs across Europe beyond project end. Through this support, we estimate a typical high potential PRO will improve its performance by 500% in the five years following intensive support, delivering at least 6 million to the European economy per PRO supported


Patent
Dsm Nutritional Products Ltd. | Date: 2016-03-30

Methods and compositions for treating modulating and/or ameliorating non-light-induced, particularly non-UV-induced, skin aging in a human, for reducing the basal MMP-10 expression in unirradiated cells of an organism and/or reducing the basal MMP-1 RNA transcription and protein translation in unirradiated cells of an organism, and/or for modulating the effects of UVA-induced RNA transcription and polypeptide translation of a matrix metalloprotease, which include administering an effective amount of -carotene, a precursor of -carotene, a salt of -carotene, or a combination of two or more thereof to an organism, particularly a mammal, more particularly a human, in need thereof.


Patent
Dsm Nutritional Products Ltd. | Date: 2015-04-01

Methods and compositions for treating modulating and/or ameliorating non-light-induced, particularly non-UV-induced, skin aging in a human, for reducing the basal MMP-10 expression in unirradiated cells of an organism and/or reducing the basal MMP-1 RNA transcription and protein translation in unirradiated cells of an organism, and/or for modulating the effects of UVA-induced RNA transcription and polypeptide translation of a matrix metalloprotease, which include administering an effective amount of -carotene, a precursor of -carotene, a salt of -carotene, or a combination of two or more thereof to an organism, particularly a mammal, more particularly a human, in need thereof.


Grant
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.96M | Year: 2012

One of achievements of developed societies has been the remarkable extension of human lifespan. In the upcoming decades the number of Europeans with advanced age will increase dramatically. It is evident that age-associated diseases will become much more prevalent. This poses challenges for society but also opportunities for commercial enterprises that develop strategies to combat deleterious consequences of ageing. However, our understanding of the mechanisms that contribute to ageing and its associated pathologies remain superficial and therapeutic or nutritional interventions unexplored. The complex nature of ageing as a scientific field calls for a multidisciplinary approach where teams of academic and industrial researchers join forces. The objective of this Network is to provide training in the biology of ageing to 11 Early Stage and 4 Experienced Researchers. We have assembled a premier group of scientists that focus their activities on the molecular mechanisms that underlie ageing, with an emphasis on how maintenance of genomic integrity in self-renewing tissues is preserved under different metabolic rates. The key aim of this training program is the elucidation of the molecular pathway by which intrinsic genomic integrity can be modified by the extrinsic rate of metabolism. Our Network consists of 10 full and 2 associated partners, representing 7 Member states and Switzerland and Canada, and include 4 commercial enterprises. Multiple complementary training schemes have been implemented in the Network. These include specific research projects (including multiple academic and industrial secondments), a variety of dedicated courses organized by the academic partners of the Network, and finally, training organized by the industrial partners of the Network. Trainees will become experts in the multidisciplinary field of ageing, and are expected to constitute future leaders in the field of ageing science and shape commercial activities in this realm.

Loading DSM Nutritional Products Ltd collaborators
Loading DSM Nutritional Products Ltd collaborators